Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
News Sep 27, 2012
Evotec AG has announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec.
The milestone was for the transition of an oncology programme into pre-clinical profiling.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the seventeenth milestone achieved as part of our alliance with Boehringer Ingelheim and represents an important transition of a compound into pre-clinical profiling. We are pleased the collaborative efforts of teams from Evotec and Boehringer Ingelheim continue to show success in progressing compounds towards the clinic.”
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019